KRAS G12C–mutant NCI-H2122, NCI-H358 (NSCLC) and MiaPaCa-2 (PDAC) cells were subjected to in vitro MRTX1257 and selinexor treatments at different dose combinations. Here, KRAS is linked to non-small cell lung carcinoma.